1. Home
  2. UAA vs MESO Comparison

UAA vs MESO Comparison

Compare UAA & MESO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Under Armour Inc.

UAA

Under Armour Inc.

HOLD

Current Price

$4.33

Market Cap

2.2B

ML Signal

HOLD

Logo Mesoblast Limited

MESO

Mesoblast Limited

HOLD

Current Price

$17.79

Market Cap

1.8B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
UAA
MESO
Founded
1996
2004
Country
United States
Australia
Employees
N/A
N/A
Industry
Apparel
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.2B
1.8B
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
UAA
MESO
Price
$4.33
$17.79
Analyst Decision
Hold
Strong Buy
Analyst Count
19
2
Target Price
$6.34
$24.00
AVG Volume (30 Days)
8.1M
211.8K
Earning Date
11-06-2025
08-28-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$5,049,070,000.00
$17,198,000.00
Revenue This Year
N/A
$465.44
Revenue Next Year
$1.54
$75.37
P/E Ratio
N/A
N/A
Revenue Growth
N/A
191.39
52 Week Low
$4.13
$9.61
52 Week High
$10.28
$22.00

Technical Indicators

Market Signals
Indicator
UAA
MESO
Relative Strength Index (RSI) 41.98 56.73
Support Level $4.29 $16.43
Resistance Level $4.55 $17.65
Average True Range (ATR) 0.14 0.59
MACD -0.01 0.16
Stochastic Oscillator 14.77 56.31

Price Performance

Historical Comparison
UAA
MESO

About UAA Under Armour Inc.

Under Armour develops, markets, and distributes athletic apparel, footwear, and accessories in North America, Asia-Pacific, Europe, and elsewhere. Consumers of its performance-based clothing and shoes include professional and amateur athletes, sponsored college and professional teams, and people with active lifestyles. The company sells merchandise through direct-to-consumer, including e-commerce and more than 400 combined factory house and brand house stores, and wholesale channels. The Baltimore-based company was founded in 1996 and is led by controlling shareholder Kevin Plank.

About MESO Mesoblast Limited

Mesoblast Ltd is a commercial-stage biotechnology company and a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The company's product candidates include: Ryoncil (remestemcel-L) for the treatment of steroid-refractory acute graft versus host disease, as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of an adult stem cell technology platform for commercialization.

Share on Social Networks: